Identification

Name
Obinutuzumab
Accession Number
DB08935
Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Obinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. There is a black box warning of fatal Hepatitis B Virus (HBV) reactivation and fatal Progressive Multifocal Leukoencephalopathy (PML).

Protein structure
Db08935
Protein chemical formula
C6512H10060N1712O2020S44
Protein average weight
146100.0 Da
Sequences
Not Available
Synonyms
  • Afutuzumab
External IDs
GA-101
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
GazyvaInjection, solution, concentrate1000 mg/40mLIntravenousGenentech, Inc.2013-11-01Not applicableUs
GazyvaSolution25 mgIntravenousHoffmann La Roche2014-11-28Not applicableCanada
Categories
UNII
O43472U9X8
CAS number
949142-50-1

Pharmacology

Indication

Obinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia.

Structured Indications
Not Available
Pharmacodynamics

Obinutuzumab is more potent than rituximab in depleting B-cells, antitumor activity, and tumor regression.

Mechanism of action

In contrast to rituximab, which is a classic type I CD20 antibody, obinutuzumab binds to type II CD20 antibodies. This allows obinutuzumab to have a much higher induction of antibody-dependant cytotoxicity and a higher direct cytotoxic effect than the classic CD20 antibodies.

TargetActionsOrganism
AB-lymphocyte antigen CD20
antibody
Human
Absorption

Obinutuzumab is administered intravenously, so its absorption is 100%.

Volume of distribution

Obinutuzumab has a volume of distribution of about 3.8 L.

Protein binding

Obinutuzumab does not bind to plasma proteins.

Metabolism

Obinutuzumab is not metabolized by the liver.

Route of elimination

The route of elimination of obinutuzumab was not indicated (FDA label).

Half life

The half life of obinutuzumab is 28.4 days.

Clearance

The clearance of obinutuzumab is 0.09L/day.

Toxicity

The most serious toxicities observed with obinutuzumab are Hepatitis B virus (HBV) reactivation and progressive multifocal leukoencephalopathy (PML). HBV reactivation can occur with all anti-CD20 antibodies and can result in hepatic failure, fulminant hepatitis, and death. PML occurs as a result of JC virus infection and can be fatal as well. Other common but less serious adverse reactions include infusion reactions (pre-treat with glucocorticoids, acetaminophen, and anti-histamine to prevent this), neutropenia, thrombocytopenia, and Tumor Lysis Syndrome (TLS) (pre-treat patients, especially with a high lymphocyte count and/or a high tumor burden, with anti-hyperuricemics and hydration). It is also recommended to NOT administer live virus vaccinations prior to or during obinutuzumab treatment.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Obinutuzumab.Approved
AcebutololAcebutolol may increase the hypotensive activities of Obinutuzumab.Approved
AcenocoumarolThe risk or severity of adverse effects can be increased when Acenocoumarol is combined with Obinutuzumab.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Obinutuzumab.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Obinutuzumab.Experimental
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Obinutuzumab.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Aldesleukin.Approved
AliskirenAliskiren may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Obinutuzumab.Approved, Withdrawn
AlprostadilThe risk or severity of adverse effects can be increased when Alprostadil is combined with Obinutuzumab.Approved, Investigational
AmbrisentanAmbrisentan may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Obinutuzumab.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Amiloride.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Obinutuzumab.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Obinutuzumab.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Obinutuzumab.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Obinutuzumab.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Amyl Nitrite.Approved
AnagrelideThe risk or severity of adverse effects can be increased when Anagrelide is combined with Obinutuzumab.Approved
AncrodThe risk or severity of adverse effects can be increased when Ancrod is combined with Obinutuzumab.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Obinutuzumab.Investigational
Antithrombin III humanThe risk or severity of adverse effects can be increased when Antithrombin III human is combined with Obinutuzumab.Approved
ApixabanThe risk or severity of adverse effects can be increased when Apixaban is combined with Obinutuzumab.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Obinutuzumab.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Apraclonidine.Approved
ArdeparinThe risk or severity of adverse effects can be increased when Ardeparin is combined with Obinutuzumab.Approved, Investigational, Withdrawn
ArgatrobanThe risk or severity of adverse effects can be increased when Argatroban is combined with Obinutuzumab.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Obinutuzumab.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Obinutuzumab.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Obinutuzumab.Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Obinutuzumab.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Azilsartan medoxomil.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Obinutuzumab.Experimental
BarbitalBarbital may increase the hypotensive activities of Obinutuzumab.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Obinutuzumab.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Obinutuzumab.Investigational
BecaplerminThe risk or severity of adverse effects can be increased when Becaplermin is combined with Obinutuzumab.Approved, Investigational
BelimumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Belimumab.Approved
BenazeprilBenazepril may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Obinutuzumab.Approved
BepridilBepridil may increase the hypotensive activities of Obinutuzumab.Approved, Withdrawn
BeraprostThe risk or severity of adverse effects can be increased when Beraprost is combined with Obinutuzumab.Investigational
BetaxololBetaxolol may increase the hypotensive activities of Obinutuzumab.Approved
BethanidineBethanidine may increase the hypotensive activities of Obinutuzumab.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Obinutuzumab.Approved, Investigational
BietaserpineBietaserpine may increase the hypotensive activities of Obinutuzumab.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Obinutuzumab.Approved
BivalirudinThe risk or severity of adverse effects can be increased when Bivalirudin is combined with Obinutuzumab.Approved, Investigational
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Obinutuzumab.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
BQ-123BQ-123 may increase the hypotensive activities of Obinutuzumab.Investigational
BretyliumBretylium may increase the hypotensive activities of Obinutuzumab.Approved
BrimonidineBrimonidine may increase the hypotensive activities of Obinutuzumab.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Obinutuzumab.Approved, Investigational
BuflomedilThe risk or severity of adverse effects can be increased when Buflomedil is combined with Obinutuzumab.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Obinutuzumab.Approved, Investigational
BupranololBupranolol may increase the hypotensive activities of Obinutuzumab.Approved
ButylphthalideThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Obinutuzumab.Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Obinutuzumab.Approved
CadralazineCadralazine may increase the hypotensive activities of Obinutuzumab.Experimental
CafedrineCafedrine may increase the hypotensive activities of Obinutuzumab.Investigational
CanagliflozinThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Canagliflozin.Approved
Candesartan cilexetilCandesartan may increase the hypotensive activities of Obinutuzumab.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Obinutuzumab.Experimental
CangrelorThe risk or severity of adverse effects can be increased when Cangrelor is combined with Obinutuzumab.Approved
CaptoprilCaptopril may increase the hypotensive activities of Obinutuzumab.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Obinutuzumab.Approved
CarteololCarteolol may increase the hypotensive activities of Obinutuzumab.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
CeliprololCeliprolol may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
CertoparinThe risk or severity of adverse effects can be increased when Certoparin is combined with Obinutuzumab.Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Obinutuzumab.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Obinutuzumab.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Obinutuzumab.Approved
CicletanineCicletanine may increase the hypotensive activities of Obinutuzumab.Investigational
CilazaprilCilazapril may increase the hypotensive activities of Obinutuzumab.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Obinutuzumab.Approved
CilostazolThe risk or severity of adverse effects can be increased when Cilostazol is combined with Obinutuzumab.Approved
Citric AcidThe risk or severity of adverse effects can be increased when Citric Acid is combined with Obinutuzumab.Nutraceutical, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Obinutuzumab.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Obinutuzumab.Approved, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Obinutuzumab.Approved
ClopidogrelThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Obinutuzumab.Approved, Nutraceutical
CloranololCloranolol may increase the hypotensive activities of Obinutuzumab.Experimental
CloricromenThe risk or severity of adverse effects can be increased when Cloricromen is combined with Obinutuzumab.Experimental
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Obinutuzumab.Approved
ClozapineThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Clozapine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Obinutuzumab.Approved, Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Obinutuzumab.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Obinutuzumab.Approved
CyclopenthiazideCyclopenthiazide may increase the hypotensive activities of Obinutuzumab.Experimental
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Obinutuzumab.Approved, Investigational
CyclothiazideCyclothiazide may increase the hypotensive activities of Obinutuzumab.Approved
CymarinCymarin may decrease the cardiotoxic activities of Obinutuzumab.Experimental
Dabigatran etexilateThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Obinutuzumab.Approved
DalteparinThe risk or severity of adverse effects can be increased when Dalteparin is combined with Obinutuzumab.Approved
DanaparoidThe risk or severity of adverse effects can be increased when Danaparoid is combined with Obinutuzumab.Approved, Withdrawn
DapagliflozinThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Dapagliflozin.Approved
DarexabanThe risk or severity of adverse effects can be increased when Darexaban is combined with Obinutuzumab.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Obinutuzumab.Approved
DefibrotideThe risk or severity of adverse effects can be increased when Defibrotide is combined with Obinutuzumab.Approved, Investigational
DelaprilDelapril may increase the hypotensive activities of Obinutuzumab.Experimental
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Obinutuzumab.Approved
DeserpidineDeserpidine may increase the hypotensive activities of Obinutuzumab.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Obinutuzumab.Approved
DesirudinThe risk or severity of adverse effects can be increased when Desirudin is combined with Obinutuzumab.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Obinutuzumab.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Dexmedetomidine.Approved, Vet Approved
DextranThe risk or severity of adverse effects can be increased when Dextran is combined with Obinutuzumab.Approved, Vet Approved
Dextran 40The risk or severity of adverse effects can be increased when Dextran 40 is combined with Obinutuzumab.Approved
Dextran 70The risk or severity of adverse effects can be increased when Dextran 70 is combined with Obinutuzumab.Approved
Dextran 75The risk or severity of adverse effects can be increased when Dextran 75 is combined with Obinutuzumab.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Obinutuzumab.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Diclofenamide.Approved
DicoumarolThe risk or severity of adverse effects can be increased when Dicoumarol is combined with Obinutuzumab.Approved
diethylnorsperminediethylnorspermine may increase the hypotensive activities of Obinutuzumab.Investigational
DigitoxinDigitoxin may decrease the cardiotoxic activities of Obinutuzumab.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Obinutuzumab.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Obinutuzumab.Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Obinutuzumab.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Obinutuzumab.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Obinutuzumab.Approved, Investigational
DorzolamideDorzolamide may increase the hypotensive activities of Obinutuzumab.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Obinutuzumab.Approved
DuloxetineObinutuzumab may increase the orthostatic hypotensive activities of Duloxetine.Approved
Edetic AcidThe risk or severity of adverse effects can be increased when Edetic Acid is combined with Obinutuzumab.Approved, Vet Approved
EdoxabanThe risk or severity of adverse effects can be increased when Edoxaban is combined with Obinutuzumab.Approved
EfonidipineEfonidipine may increase the hypotensive activities of Obinutuzumab.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Empagliflozin.Approved
EnalaprilEnalapril may increase the hypotensive activities of Obinutuzumab.Approved, Vet Approved
EnalaprilatEnalaprilat may increase the hypotensive activities of Obinutuzumab.Approved
EndralazineEndralazine may increase the hypotensive activities of Obinutuzumab.Experimental
EnoxaparinThe risk or severity of adverse effects can be increased when Enoxaparin is combined with Obinutuzumab.Approved
EpanololEpanolol may increase the hypotensive activities of Obinutuzumab.Experimental
EpinastineThe risk or severity of adverse effects can be increased when Epinastine is combined with Obinutuzumab.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Eplerenone.Approved
EplivanserinThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Obinutuzumab.Investigational
eplivanserineThe risk or severity of adverse effects can be increased when eplivanserine is combined with Obinutuzumab.Investigational
EpoprostenolEpoprostenol may increase the hypotensive activities of Obinutuzumab.Approved
EprosartanEprosartan may increase the hypotensive activities of Obinutuzumab.Approved
EptifibatideThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Obinutuzumab.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Esmolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Etacrynic acid.Approved
Ethyl biscoumacetateThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Obinutuzumab.Withdrawn
FelodipineFelodipine may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
FenoldopamFenoldopam may increase the hypotensive activities of Obinutuzumab.Approved
Ferulic acidFerulic acid may increase the hypotensive activities of Obinutuzumab.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Obinutuzumab.Approved
FingolimodObinutuzumab may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FluindioneThe risk or severity of adverse effects can be increased when Fluindione is combined with Obinutuzumab.Investigational
FondaparinuxThe risk or severity of adverse effects can be increased when Fondaparinux is combined with Obinutuzumab.Investigational
Fondaparinux sodiumThe risk or severity of adverse effects can be increased when Fondaparinux sodium is combined with Obinutuzumab.Approved, Investigational
FosinoprilFosinopril may increase the hypotensive activities of Obinutuzumab.Approved
FurosemideThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Furosemide.Approved, Vet Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Obinutuzumab.Investigational
GabexateThe risk or severity of adverse effects can be increased when Gabexate is combined with Obinutuzumab.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Obinutuzumab.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Obinutuzumab.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Obinutuzumab.Approved
GuanazodineGuanazodine may increase the hypotensive activities of Obinutuzumab.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Obinutuzumab.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
GuanoclorGuanoclor may increase the hypotensive activities of Obinutuzumab.Experimental
GuanoxabenzGuanoxabenz may increase the hypotensive activities of Obinutuzumab.Experimental
GuanoxanGuanoxan may increase the hypotensive activities of Obinutuzumab.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Obinutuzumab.Approved, Vet Approved
HeparinThe risk or severity of adverse effects can be increased when Heparin is combined with Obinutuzumab.Approved, Investigational
HexamethoniumHexamethonium may increase the hypotensive activities of Obinutuzumab.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Obinutuzumab.Approved
HydralazineHydralazine may increase the hypotensive activities of Obinutuzumab.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Obinutuzumab.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
HydroxytyrosolThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Obinutuzumab.Investigational
IbudilastThe risk or severity of adverse effects can be increased when Ibudilast is combined with Obinutuzumab.Approved, Investigational
Icosapent ethylThe risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Obinutuzumab.Approved, Nutraceutical
IdraparinuxThe risk or severity of adverse effects can be increased when Idraparinux is combined with Obinutuzumab.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Obinutuzumab.Approved, Withdrawn
IfetrobanThe risk or severity of adverse effects can be increased when Ifetroban is combined with Obinutuzumab.Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Obinutuzumab.Approved, Investigational
ImidaprilImidapril may increase the hypotensive activities of Obinutuzumab.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Obinutuzumab.Approved
IndapamideIndapamide may increase the hypotensive activities of Obinutuzumab.Approved
IndenololIndenolol may increase the hypotensive activities of Obinutuzumab.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Obinutuzumab.Investigational
IndoraminIndoramin may increase the hypotensive activities of Obinutuzumab.Withdrawn
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Obinutuzumab.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Obinutuzumab.Investigational
IrbesartanIrbesartan may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Obinutuzumab.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Obinutuzumab.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Obinutuzumab.Approved
KetanserinKetanserin may increase the hypotensive activities of Obinutuzumab.Investigational
LabetalolLabetalol may increase the hypotensive activities of Obinutuzumab.Approved
LacidipineLacidipine may increase the hypotensive activities of Obinutuzumab.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Obinutuzumab.Experimental
LatanoprostLatanoprost may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Leflunomide.Approved, Investigational
LepirudinThe risk or severity of adverse effects can be increased when Lepirudin is combined with Obinutuzumab.Approved
LercanidipineLercanidipine may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
LetaxabanThe risk or severity of adverse effects can be increased when Letaxaban is combined with Obinutuzumab.Investigational
LevobunololThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Obinutuzumab.Approved, Investigational
LevodopaObinutuzumab may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Obinutuzumab.Approved, Investigational
LinsidomineLinsidomine may increase the hypotensive activities of Obinutuzumab.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
LofexidineLofexidine may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
LosartanLosartan may increase the hypotensive activities of Obinutuzumab.Approved
MacitentanMacitentan may increase the hypotensive activities of Obinutuzumab.Approved
ManidipineManidipine may increase the hypotensive activities of Obinutuzumab.Approved
MannitolThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Mannitol.Approved, Investigational
MecamylamineMecamylamine may increase the hypotensive activities of Obinutuzumab.Approved
MelagatranThe risk or severity of adverse effects can be increased when Melagatran is combined with Obinutuzumab.Experimental
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Obinutuzumab.Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Obinutuzumab.Approved
MethoserpidineMethoserpidine may increase the hypotensive activities of Obinutuzumab.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Methyclothiazide.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Obinutuzumab.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Obinutuzumab.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Obinutuzumab.Experimental
MetipranololMetipranolol may increase the hypotensive activities of Obinutuzumab.Approved
MetolazoneMetolazone may increase the hypotensive activities of Obinutuzumab.Approved
MetoprololMetoprolol may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
MetyrosineMetyrosine may increase the hypotensive activities of Obinutuzumab.Approved
MibefradilMibefradil may increase the hypotensive activities of Obinutuzumab.Investigational, Withdrawn
MilrinoneThe risk or severity of adverse effects can be increased when Milrinone is combined with Obinutuzumab.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Obinutuzumab.Approved
MoexiprilMoexipril may increase the hypotensive activities of Obinutuzumab.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Obinutuzumab.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Obinutuzumab.Approved
MuzolimineMuzolimine may increase the hypotensive activities of Obinutuzumab.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Obinutuzumab.Approved, Investigational
NadololNadolol may increase the hypotensive activities of Obinutuzumab.Approved
NadroparinThe risk or severity of adverse effects can be increased when Nadroparin is combined with Obinutuzumab.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Obinutuzumab.Approved, Investigational
NaftopidilNaftopidil may increase the hypotensive activities of Obinutuzumab.Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Natalizumab.Approved, Investigational
NebivololNebivolol may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Nesiritide.Approved, Investigational
NicardipineNicardipine may increase the hypotensive activities of Obinutuzumab.Approved
NicorandilNicorandil may increase the hypotensive activities of Obinutuzumab.Approved
NifedipineThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Nifedipine.Approved
NiguldipineNiguldipine may increase the hypotensive activities of Obinutuzumab.Experimental
NilvadipineNilvadipine may increase the hypotensive activities of Obinutuzumab.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Obinutuzumab.Approved, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Obinutuzumab.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Obinutuzumab.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Obinutuzumab.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Obinutuzumab.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Nitroglycerin.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Obinutuzumab.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Obinutuzumab.Experimental
OlmesartanOlmesartan may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OmapatrilatOmapatrilat may increase the hypotensive activities of Obinutuzumab.Investigational
OtamixabanThe risk or severity of adverse effects can be increased when Otamixaban is combined with Obinutuzumab.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Obinutuzumab.Approved
OxprenololOxprenolol may increase the hypotensive activities of Obinutuzumab.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Obinutuzumab.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Papaverine.Approved
PargylinePargyline may increase the hypotensive activities of Obinutuzumab.Approved
PenbutololPenbutolol may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Obinutuzumab.Approved, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Obinutuzumab.Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Obinutuzumab.Approved
PentoxifyllineThe risk or severity of adverse effects can be increased when Pentoxifylline is combined with Obinutuzumab.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Obinutuzumab.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Obinutuzumab.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Phenelzine.Approved
PhenindioneThe risk or severity of adverse effects can be increased when Phenindione is combined with Obinutuzumab.Approved, Investigational
PhenobarbitalPhenobarbital may increase the hypotensive activities of Obinutuzumab.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Obinutuzumab.Approved
PhenprocoumonThe risk or severity of adverse effects can be increased when Phenprocoumon is combined with Obinutuzumab.Approved, Investigational
PhentolaminePhentolamine may increase the hypotensive activities of Obinutuzumab.Approved
PicotamideThe risk or severity of adverse effects can be increased when Picotamide is combined with Obinutuzumab.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Obinutuzumab.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Obinutuzumab.Withdrawn
PindololPindolol may increase the hypotensive activities of Obinutuzumab.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Pipamperone.Approved
PolythiazidePolythiazide may increase the hypotensive activities of Obinutuzumab.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Pramipexole.Approved, Investigational
PrasugrelThe risk or severity of adverse effects can be increased when Prasugrel is combined with Obinutuzumab.Approved
PrazosinPrazosin may increase the hypotensive activities of Obinutuzumab.Approved
PrimidonePrimidone may increase the hypotensive activities of Obinutuzumab.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Propofol.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Obinutuzumab.Experimental
Protein CThe risk or severity of adverse effects can be increased when Protein C is combined with Obinutuzumab.Approved
Protein S humanThe risk or severity of adverse effects can be increased when Protein S human is combined with Obinutuzumab.Approved
ProtocatechualdehydeThe risk or severity of adverse effects can be increased when Protocatechualdehyde is combined with Obinutuzumab.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Quetiapine.Approved
QuinaprilQuinapril may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Obinutuzumab.Approved
RamatrobanThe risk or severity of adverse effects can be increased when Ramatroban is combined with Obinutuzumab.Investigational
RamiprilRamipril may increase the hypotensive activities of Obinutuzumab.Approved
RasagilineThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Obinutuzumab.Approved
RescinnamineRescinnamine may increase the hypotensive activities of Obinutuzumab.Approved
ReserpineReserpine may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Obinutuzumab.Approved, Experimental, Investigational
ReviparinThe risk or severity of adverse effects can be increased when Reviparin is combined with Obinutuzumab.Approved
RidogrelThe risk or severity of adverse effects can be increased when Ridogrel is combined with Obinutuzumab.Approved
RilmenidineRilmenidine may increase the hypotensive activities of Obinutuzumab.Investigational
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Obinutuzumab.Investigational
RiociguatRiociguat may increase the hypotensive activities of Obinutuzumab.Approved
RisperidoneObinutuzumab may increase the hypotensive activities of Risperidone.Approved, Investigational
RivaroxabanThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Obinutuzumab.Approved
RoflumilastRoflumilast may increase the immunosuppressive activities of Obinutuzumab.Approved
RopiniroleThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Ropivacaine.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Obinutuzumab.Approved
RotigotineThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Rotigotine.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Obinutuzumab.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Sacubitril.Approved
SaprisartanSaprisartan may increase the hypotensive activities of Obinutuzumab.Experimental
SarpogrelateThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Obinutuzumab.Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Obinutuzumab.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagSelexipag may increase the hypotensive activities of Obinutuzumab.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Obinutuzumab.Approved, Vet Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Obinutuzumab.Approved
SitaxentanSitaxentan may increase the hypotensive activities of Obinutuzumab.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Sotalol.Approved
SpiraprilSpirapril may increase the hypotensive activities of Obinutuzumab.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Spironolactone.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Obinutuzumab.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Obinutuzumab.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Streptokinase.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Sufentanil.Approved, Investigational
SulodexideThe risk or severity of adverse effects can be increased when Sulodexide is combined with Obinutuzumab.Approved, Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Obinutuzumab.Approved, Investigational
TalinololTalinolol may increase the hypotensive activities of Obinutuzumab.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Tamsulosin.Approved, Investigational
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Obinutuzumab.Investigational
TelmisartanTelmisartan may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
TemocaprilTemocapril may increase the hypotensive activities of Obinutuzumab.Experimental, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Terazosin.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
TesmilifeneThe risk or severity of adverse effects can be increased when Tesmilifene is combined with Obinutuzumab.Investigational
TetrahydropalmatineTetrahydropalmatine may increase the hypotensive activities of Obinutuzumab.Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Obinutuzumab.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Thalidomide.Approved, Investigational, Withdrawn
TheodrenalineTheodrenaline may increase the hypotensive activities of Obinutuzumab.Investigational
ThiamylalThiamylal may increase the hypotensive activities of Obinutuzumab.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Obinutuzumab.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Thioridazine.Approved, Withdrawn
TiboloneTibolone may increase the hypotensive activities of Obinutuzumab.Approved
TiclopidineThe risk or severity of adverse effects can be increased when Ticlopidine is combined with Obinutuzumab.Approved
TicrynafenTicrynafen may increase the hypotensive activities of Obinutuzumab.Withdrawn
TimololTimolol may increase the hypotensive activities of Obinutuzumab.Approved
TirofibanThe risk or severity of adverse effects can be increased when Tirofiban is combined with Obinutuzumab.Approved
TizanidineThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Tizanidine.Approved
TofacitinibObinutuzumab may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazolineTolazoline may increase the hypotensive activities of Obinutuzumab.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Tolcapone.Approved, Withdrawn
TolonidineTolonidine may increase the hypotensive activities of Obinutuzumab.Experimental
TorasemideTorasemide may increase the hypotensive activities of Obinutuzumab.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Obinutuzumab.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Obinutuzumab.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Tranylcypromine.Approved
TrapidilThe risk or severity of adverse effects can be increased when Trapidil is combined with Obinutuzumab.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Obinutuzumab.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Obinutuzumab.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Triamterene.Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Obinutuzumab.Approved, Vet Approved
TriflusalThe risk or severity of adverse effects can be increased when Triflusal is combined with Obinutuzumab.Approved
TrimazosinTrimazosin may increase the hypotensive activities of Obinutuzumab.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
TroxerutinThe risk or severity of adverse effects can be increased when Troxerutin is combined with Obinutuzumab.Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of Obinutuzumab.Approved
UrapidilUrapidil may increase the hypotensive activities of Obinutuzumab.Investigational
ValsartanValsartan may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
VerapamilThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Verapamil.Approved
VincamineVincamine may increase the hypotensive activities of Obinutuzumab.Experimental
VinpocetineVinpocetine may increase the hypotensive activities of Obinutuzumab.Investigational
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Obinutuzumab.Approved
WarfarinThe risk or severity of adverse effects can be increased when Warfarin is combined with Obinutuzumab.Approved
XimelagatranThe risk or severity of adverse effects can be increased when Ximelagatran is combined with Obinutuzumab.Approved, Investigational, Withdrawn
XipamideXipamide may increase the hypotensive activities of Obinutuzumab.Experimental
XylometazolineXylometazoline may increase the hypotensive activities of Obinutuzumab.Approved
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Obinutuzumab.Approved
ZofenoprilZofenopril may increase the hypotensive activities of Obinutuzumab.Experimental
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Obinutuzumab.Approved
Food Interactions
  • Echinacea: diminished therapeutic effect of immunosuppressants

References

Synthesis Reference

Robak T: GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs. 2009 Jun;10(6):588-96.

General References
Not Available
External Links
KEGG Drug
D09321
PubChem Substance
347910388
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Obinutuzumab
ATC Codes
L01XC15 — Obinutuzumab
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
FDA label
Download (484 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)1
1Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemia, Prolymphocytic / Small Lymphocytic Lymphoma (SLL)1
1Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Lymphocytic Leukemia, Chronic1
1Active Not RecruitingTreatmentDiffuse Large B-Cell Lymphoma, Lymphoma Follicular / Diffuse Large B-Cell Lymphoma, Lymphoma, Follicular1
1Active Not RecruitingTreatmentKidney Failure,Chronic1
1Active Not RecruitingTreatmentLymphocytic Leukemia, Chronic1
1Active Not RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentLymphocytic Leukemia, Chronic1
1CompletedTreatmentLymphocytic Leukemia, Chronic, Diffuse Large B-cell Lymphoma, Follicular Lymphoma / Lymphocytic Leukemia, Chronic, Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma1
1CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
1Not Yet RecruitingTreatmentBurkitt's Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Malignant Lymphomas / Non-Hodgkin's Lymphoma (NHL)1
1RecruitingTreatmentB-Cell Chronic Lymphocytic Leukemia / Chronic Lymphocytic Leukaemia (CLL)1
1RecruitingTreatmentB-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma / Grade 1 Follicular Lymphoma / Grade 2 Follicular Lymphoma / Grade 3a Follicular Lymphoma / Recurrent Burkitt Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Follicular Lymphoma / Recurrent Marginal Zone Lymphoma / Refractory Burkitt Lymphoma / Refractory Diffuse Large B-Cell Lymphoma / Refractory Follicular Lymphoma / Transformed Recurrent Non-Hodgkin Lymphoma1
1RecruitingTreatmentB-Cell Malignancies1
1RecruitingTreatmentB-cell Lymphoid Malignancies1
1RecruitingTreatmentCLL / Richter's Syndrome1
1RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)3
1RecruitingTreatmentFollicular Lymphoma (FL)1
1RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Non-Hodgkin's Lymphoma (NHL)1
1RecruitingTreatmentMalignant Lymphomas2
1RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)2
1RecruitingTreatmentRelapsed or Refractory Follicular Lymphoma1
1RecruitingTreatmentSolid Cancers1
1RecruitingTreatmentSolid Cancers / Tumors, Solid1
1SuspendedTreatmentFollicular Lymphoma (FL)1
1TerminatedTreatmentLymphocytic Leukemia, Chronic / Small Lymphocytic Lymphoma (SLL)1
1, 2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Refractory Chronic Lymphocytic Leukemia1
1, 2Active Not RecruitingTreatmentDiffuse Large B-Cell Lymphoma, Lymphoma, Follicular / Follicular Lymphoma, Diffuse Large B-Cell Lymphoma / Lymphoma, Follicular, Diffuse Large B-Cell Lymphoma1
1, 2Active Not RecruitingTreatmentDiffuse Large B-Cell Lymphoma, Lymphoma, Non Hodgkin, Lymphoma, Follicular / Malignant Lymphomas1
1, 2Active Not RecruitingTreatmentLymphoma, B-Cell, Non-Hodgkin's Lymphoma / Non Hodgkin Lymphoma (NHL)1
1, 2Active Not RecruitingTreatmentMalignant Lymphomas1
1, 2Active Not RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
1, 2CompletedTreatmentCD20+ Follicular Lymphoma1
1, 2CompletedTreatmentMalignant Lymphomas1
1, 2RecruitingTreatmentAnemias / B-Cell Prolymphocytic Leukemia / Fevers / Grade 1 Follicular Lymphoma / Grade 2 Follicular Lymphoma / Grade 3a Follicular Lymphoma / Hairy Cell Leukemia (HCL) / Lymphadenopathy / Lymphocytosis / Lymphoplasmacytic Lymphoma / Mantle Cell Lymphoma (MCL) / Marginal Zone Lymphoma / Night Sweats / Obese experiencing rapid weight loss / Recurrent Chronic Lymphocytic Leukemia / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Small Lymphocytic Lymphoma / Richter's Syndrome / Splenomegaly / Thrombocytopenias / Tiredness1
1, 2RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)1
1, 2RecruitingTreatmentFollicular Lymphoma (FL) / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
1, 2RecruitingTreatmentFollicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II) / Follicular Lymphoma Patients (Phase IB)1
1, 2RecruitingTreatmentLeukemia, Lymphocytic, Chronic, B-Cell1
1, 2RecruitingTreatmentMalignant Lymphomas1
1, 2RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
1, 2RecruitingTreatmentRelapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma1
2Active Not RecruitingTreatmentChronic Lymphocytic Leucemia2
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)2
2Active Not RecruitingTreatmentIndolent Non-Hodgkin's Lymphomas1
2Active Not RecruitingTreatmentLymphoma, B-Cell1
2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL)1
2CompletedTreatmentIndolent Non-Hodgkin's Lymphomas1
2CompletedTreatmentLymphocytic Leukemia, Chronic1
2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
2Not Yet RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)1
2Not Yet RecruitingTreatmentFollicular Lymphoma (FL) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Marginal Zone Lymphoma / Mucosa Associated Lymphoid Tissue1
2Not Yet RecruitingTreatmentMantle Cell Lymphoma (MCL)2
2Not Yet RecruitingTreatmentMarginal Zone Lymphoma1
2Not Yet RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)2
2RecruitingTreatmentBurkitt's Lymphoma / CD20+ Lymphoblastic Lymphoma / Follicular Lymphoma, Grade III / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Non-Hodgkin's Lymphoma (NHL) / Primary Mediastinal B-Cell Lymphoma1
2RecruitingTreatmentCD20 Positive Diffuse Large B-cell Lymphoma / Elderly Unfit Patients1
2RecruitingTreatmentCentral Nervous System Lymphoma1
2RecruitingTreatmentChronic Lymphocytic Leucemia2
2RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)2
2RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias1
2RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Richter's Transformation1
2RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)1
2RecruitingTreatmentFollicular Lymphoma (FL)1
2RecruitingTreatmentGrade 1 Follicular Lymphoma / Grade 2 Follicular Lymphoma / Grade 3a Follicular Lymphoma / Recurrent Follicular Lymphoma / Refractory Follicular Lymphoma1
2RecruitingTreatmentGraft Versus Host Disease (GVHD)1
2RecruitingTreatmentLeukemia, Lymphocytic, Chronic1
2RecruitingTreatmentLeukemia, Lymphocytic, Chronic, B-Cell1
2RecruitingTreatmentLeukemias1
2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2RecruitingTreatmentMantle Cell Lymphoma (MCL) / Non Hodgkin Lymphoma (NHL) / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentNephritis, Lupus1
2RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentRecurrent Mantle Cell Lymphoma / Refractory Mantle Cell Lymphoma1
2RecruitingTreatmentRelapsed/Refractory Follicular Non-Hodgkin Lymphoma1
2RecruitingTreatmentRichter's Syndrome1
2RecruitingTreatmentWaldenstrom's Macroglobulinemia (WM)1
2TerminatedTreatmentLymphatic Diseases / Lymphoma, B-Cell1
2WithdrawnTreatmentPost-Transplant Lymphoproliferative Disorder / PTLD1
3Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)3
3Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Lymphoma, Small-Cell1
3Active Not RecruitingTreatmentDiffuse Large B Cell Lymphoma CD20 Positive / Diffuse Large B Cell Lymphoma CD20+1
3Active Not RecruitingTreatmentLymphocytic Leukemia, Chronic2
3Active Not RecruitingTreatmentLymphoma, B-Cell / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
3Active Not RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)2
3CompletedTreatmentLymphocytic Leukemia, Chronic2
3RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)1
3TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL)1
Not AvailableNot Yet RecruitingNot AvailableChronic Lymphocytic Leukaemia (CLL)1
Not AvailableRecruitingNot AvailableChronic Lymphocytic Leukaemia (CLL)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, solution, concentrateIntravenous1000 mg/40mL
SolutionIntravenous25 mg
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
water solubilityWater solubleNot Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antibody
General Function
Mhc class ii protein complex binding
Specific Function
This protein may be involved in the regulation of B-cell activation and proliferation.
Gene Name
MS4A1
Uniprot ID
P11836
Uniprot Name
B-lymphocyte antigen CD20
Molecular Weight
33076.99 Da
References
  1. Robak T: GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs. 2009 Jun;10(6):588-96. [PubMed:19513948]

Drug created on January 05, 2014 13:42 / Updated on November 13, 2017 21:49